# US 2025/0367196 A1 · Compositions and methods of use for modified release minoxidil

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367196 A1
- Document ID: US20250367196A1
- Status: Published application
- Kind: A1
- Application number: 19/230,047
- Filed: 2025-06-05
- Published: 2025-12-04
- Earliest claimed: 2022-10-25
- Assignees: Veradermics Incorporated
- Applicants: Veradermics, Incorporated
- Inventors: Reid Waldman
- Web page: https://patentgrep.com/patent/US20250367196A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61P 17/14: for baldness or alopecia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating hair loss, comprising orally administering a dosage form to a human being experiencing hair loss, wherein the dosage form comprises about 4.5 mg of minoxidil or a molar equivalent amount of the pharmaceutically acceptable salt thereof,
wherein the dosage form provides:
a Cmax of minoxidil that is about 0.25 ng/ml to about 20 ng/ml, and
a Tmax of minoxidil that is about 30 to about 360 minutes,
wherein the dosage form releases from about 50% to about 98% of the about 4.5 mg minoxidil or the equivalent amount of the pharmaceutically acceptable salt thereof within about 18 hours after the oral administration.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dosage form is administered once daily.

### Claim 3 (depends on 1)

The method of claim 1, wherein the dosage form is administered twice daily.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dosage form comprises a release modifier, wherein the release modifier provides modified release of the minoxidil or the pharmaceutically acceptable salt thereof comprised in the dosage form, and orally administering the dosage form provides an AUC0-inf that is less than the AUC0-inf provided by a dosage form containing an immediate release formulation of 4.5 mg of minoxidil.

### Claim 5 (depends on 1)

The method of claim 1, wherein a blood level of minoxidil or the pharmaceutically acceptable salt thereof of about 1 ng/ml to about 20 ng/ml is maintained for at least about 8 hours.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dosage form further comprises a filler, a glidant, a lubricant, or a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the hair loss comprises female pattern hair loss.

### Claim 8 (depends on 1)

The method of claim 1, wherein the hair loss comprises hereditary hair loss.

### Claim 9 (depends on 1)

The method of claim 1, wherein the hair loss comprises telogen effluvium.

### Claim 10 (depends on 1)

The method of claim 1, wherein the hair loss comprises alopecia areata.

### Claim 11 (depends on 1)

The method of claim 1, wherein the hair loss comprises central centrifugal cicatricial alopecia.

### Claim 12 (depends on 1)

The method of claim 1, wherein the hair loss comprises lichen planopilaris.

### Claim 13 (depends on 1)

The method of claim 1, wherein the hair loss comprises traction alopecia.

### Claim 14 (depends on 1)

The method of claim 1, wherein the oral administration results in hair regrowth.

### Claim 15 (depends on 1)

The method of claim 1, wherein the dosage form comprises an enteric coating.

### Claim 16 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no tachycardia.

### Claim 17 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no symptomatic hypotension.

### Claim 18 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no premature ventricular contractions.

### Claim 19 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no symptomatic tachyarrhythmias.

### Claim 20 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no peripheral edema.

### Claim 21 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no lightheadedness.
